P53 Stabilisation Potentiates [Lu]Lu-DOTATATE Treatment in Neuroblastoma Xenografts

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2023 Oct 12

PMID 37823909

Authors

Hanna Berglund

Sara Lundsten Salomonsson

Tabassom Mohajershojai

Fernando Jose Ferrer Gago

David P Lane

Marika Nestor

Affiliations

Soon will be listed here.

Abstract

Purpose: Molecular radiotherapy is a treatment modality that is highly suitable for targeting micrometastases and [Lu]Lu-DOTATATE is currently being explored as a potential novel treatment option for high-risk neuroblastoma. p53 is a key player in the proapoptotic signalling in response to radiation-induced DNA damage and is therefore a potential target for radiosensitisation.

Methods: This study investigated the use of the p53 stabilising peptide VIP116 and [Lu]Lu-DOTATATE, either alone or in combination, for treatment of neuroblastoma tumour xenografts in mice. Initially, the uptake of [Lu]Lu-DOTATATE in the tumours was confirmed, and the efficacy of VIP116 as a monotherapy was evaluated. Subsequently, mice with neuroblastoma tumour xenografts were treated with placebo, VIP116, [Lu]Lu-DOTATATE or a combination of both agents.

Results: The results demonstrated that monotherapy with either VIP116 or [Lu]Lu-DOTATATE significantly prolonged median survival compared to the placebo group (90 and 96.5 days vs. 50.5 days, respectively). Notably, the combination treatment further improved median survival to over 120 days. Furthermore, the combination group exhibited the highest percentage of complete remission, corresponding to a twofold increase compared to the placebo group. Importantly, none of the treatments induced significant nephrotoxicity. Additionally, the therapies affected various molecular targets involved in critical processes such as apoptosis, hypoxia and angiogenesis.

Conclusion: In conclusion, the combination of VIP116 and [Lu]Lu-DOTATATE presents a promising novel treatment approach for neuroblastoma. These findings hold potential to advance research efforts towards a potential cure for this vulnerable patient population.

Citing Articles

Comparison of Lu-octreotate and Lu-octreotide for treatment in human neuroblastoma-bearing mice.

Romiani A, Simonsson K, Pettersson D, Al-Awar A, Rassol N, Bakr H Heliyon. 2024; 10(10):e31409.

PMID: 38826727 PMC: 11141386. DOI: 10.1016/j.heliyon.2024.e31409.

References

Wetz C, Apostolova I, Steffen I, Hofheinz F, Furth C, Kupitz D . Predictive Value of Asphericity in Pretherapeutic [In]DTPA-Octreotide SPECT/CT for Response to Peptide Receptor Radionuclide Therapy with [Lu]DOTATATE. Mol Imaging Biol. 2016; 19(3):437-445. DOI: 10.1007/s11307-016-1018-x. View

Kim E, Lee H, Lee Y, Sonn J, Lim Y . Ionizing Radiation Regulates Vascular Endothelial Growth Factor-A Transcription in Cultured Human Vascular Endothelial Cells Via the PERK/eIF2α/ATF4 Pathway. Int J Radiat Oncol Biol Phys. 2020; 107(3):563-570. DOI: 10.1016/j.ijrobp.2020.03.003. View

Lundsten S, Berglund H, Jha P, Krona C, Hariri M, Nelander S . p53-Mediated Radiosensitization of Lu-DOTATATE in Neuroblastoma Tumor Spheroids. Biomolecules. 2021; 11(11). PMC: 8615514. DOI: 10.3390/biom11111695. View

Senkowski W, Jarvius M, Rubin J, Lengqvist J, Gustafsson M, Nygren P . Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids. Cell Chem Biol. 2016; 23(11):1428-1438. DOI: 10.1016/j.chembiol.2016.09.013. View

Zhou Z, Zalutsky M, Chitneni S . Stapled peptides as scaffolds for developing radiotracers for intracellular targets: Preliminary evaluation of a radioiodinated MDM2-binding stapled peptide in the SJSA-1 osteosarcoma model. Bioorg Med Chem Lett. 2022; 66:128725. PMC: 9940446. DOI: 10.1016/j.bmcl.2022.128725. View

Adnan A, Basu S . Combined Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option. J Nucl Med Technol. 2020; 48(3):292-294. DOI: 10.2967/jnmt.119.237354. View

Cuperus R, Tytgat G, Leen R, Brites P, Bras J, Caron H . Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids. Int J Oncol. 2008; 32(5):1011-9. View

Chen L, Pastorino F, Berry P, Bonner J, Kirk C, Wood K . Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. Int J Cancer. 2018; 144(12):3146-3159. PMC: 6491995. DOI: 10.1002/ijc.32058. View

Ward C, Meehan J, Gray M, Kunkler I, Langdon S, Argyle D . Carbonic Anhydrase IX (CAIX), Cancer, and Radiation Responsiveness. Metabolites. 2018; 8(1). PMC: 5874614. DOI: 10.3390/metabo8010013. View

10.

Meijer A, Kruyt F, van der Zee A, Hollema H, Le P, ten Hoor K . Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br J Cancer. 2013; 109(10):2685-95. PMC: 3833221. DOI: 10.1038/bjc.2013.636. View

11.

Romiani A, Spetz J, Shubbar E, Lind D, Hallberg B, Palmer R . Neuroblastoma xenograft models demonstrate the therapeutic potential of Lu-octreotate. BMC Cancer. 2021; 21(1):950. PMC: 8386073. DOI: 10.1186/s12885-021-08551-8. View

12.

Geenen L, Nonnekens J, Konijnenberg M, Baatout S, de Jong M, Aerts A . Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol. 2021; 102-103:1-11. DOI: 10.1016/j.nucmedbio.2021.06.006. View

13.

Spiegelberg D, Mortensen A, Lundsten S, Brown C, Lane D, Nestor M . The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors. Cancer Res. 2018; 78(17):5084-5093. DOI: 10.1158/0008-5472.CAN-18-0440. View

14.

Mammatas L, Verheul H, Hendrikse N, Yaqub M, Lammertsma A, Menke-van der Houven van Oordt C . Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care. Cell Oncol (Dordr). 2014; 38(1):49-64. DOI: 10.1007/s13402-014-0194-4. View

15.

Gains J, Moroz V, Aldridge M, Wan S, Wheatley K, Laidler J . A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma. Eur J Nucl Med Mol Imaging. 2020; 47(10):2348-2357. DOI: 10.1007/s00259-020-04741-x. View

16.

Lundsten S, Spiegelberg D, Stenerlow B, Nestor M . The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells. Int J Oncol. 2019; 55(6):1287-1295. PMC: 6831206. DOI: 10.3892/ijo.2019.4888. View

17.

Saleh M, Patel M, Bauer T, Goel S, Falchook G, Shapiro G . Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2021; 27(19):5236-5247. PMC: 9401461. DOI: 10.1158/1078-0432.CCR-21-0715. View

18.

Pool S, Krenning E, Koning G, van Eijck C, Teunissen J, Kam B . Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med. 2010; 40(3):209-18. DOI: 10.1053/j.semnuclmed.2009.12.001. View

19.

Zhao Q, Liu Y, Zhang Y, Meng L, Wei J, Wang B . Role and toxicity of radiation therapy in neuroblastoma patients: A literature review. Crit Rev Oncol Hematol. 2020; 149:102924. DOI: 10.1016/j.critrevonc.2020.102924. View

20.

Albers A, ODorisio M, Balster D, CAPRARA M, Gosh P, Chen F . Somatostatin receptor gene expression in neuroblastoma. Regul Pept. 2000; 88(1-3):61-73. DOI: 10.1016/s0167-0115(99)00121-4. View